These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33797627)

  • 1. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients.
    Fukami Y; Iijima M; Koike H; Yamada S; Hashizume A; Katsuno M
    J Neurol; 2021 Oct; 268(10):3835-3844. PubMed ID: 33797627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism.
    Kira JI
    Front Neurol; 2021; 12():665136. PubMed ID: 34177770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies.
    Kmezic I; Samuelsson K; Finn A; Upate Z; Blennow K; Zetterberg H; Press R
    Eur J Neurol; 2022 Sep; 29(9):2810-2822. PubMed ID: 35638376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.
    Hayashi T; Nukui T; Piao JL; Sugimoto T; Anada R; Matsuda N; Yamamoto M; Konishi H; Dougu N; Nakatsuji Y
    Brain Behav; 2021 May; 11(5):e02084. PubMed ID: 33617139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripherin is a biomarker of axonal damage in peripheral nervous system disease.
    Keddie S; Smyth D; Keh RYS; Chou MKL; Grant D; Surana S; Heslegrave A; Zetterberg H; Wieske L; Michael M; Eftimov F; Bellanti R; Rinaldi S; Hart MS; Petzold A; Lunn MP
    Brain; 2023 Nov; 146(11):4562-4573. PubMed ID: 37435933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies.
    Mariotto S; Farinazzo A; Magliozzi R; Alberti D; Monaco S; Ferrari S
    J Peripher Nerv Syst; 2018 Sep; 23(3):174-177. PubMed ID: 29974556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal cytokine profile in neuropathy with anti-neurofascin 155 antibody.
    Ogata H; Zhang X; Yamasaki R; Fujii T; Machida A; Morimoto N; Kaida K; Masuda T; Ando Y; Kuwahara M; Kusunoki S; Nakamura Y; Matsushita T; Isobe N; Kira JI
    Ann Clin Transl Neurol; 2019 Nov; 6(11):2304-2316. PubMed ID: 31657126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Fujita A; Ogata H; Yamasaki R; Matsushita T; Kira JI
    J Neurol Sci; 2018 Jan; 384():107-112. PubMed ID: 29249367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy.
    Ogata H; Yamasaki R; Hiwatashi A; Oka N; Kawamura N; Matsuse D; Kuwahara M; Suzuki H; Kusunoki S; Fujimoto Y; Ikezoe K; Kishida H; Tanaka F; Matsushita T; Murai H; Kira J
    Ann Clin Transl Neurol; 2015 Oct; 2(10):960-71. PubMed ID: 26478896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of axo-glial junction in anti-neurofascin 155 chronic inflammatory demyelinating polyneuropathy.
    Lv H; Meng L; Yu M; Zhang W; Wang Z; Yuan Y
    Clin Neuropathol; 2021; 40(2):87-92. PubMed ID: 33261722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the patients with antibodies against nodal-paranodal junction proteins in chronic inflammatory demyelinating polyneuropathy.
    Dong M; Tai H; Yang S; Gao X; Pan H; Zhang Z
    Clin Neurol Neurosurg; 2022 Dec; 223():107521. PubMed ID: 36401951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis.
    Hu W; Xin Y; He Z; Zhao Y
    Brain Behav; 2018 Oct; 8(10):e01115. PubMed ID: 30240176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of patients with autoimmune nodopathy with anti-neurofascin155 antibodies.
    Zhang J; Hou X; Wei L; Liu J; Li S; Guo Y; Liu H; Jiang Y
    Front Immunol; 2024; 15():1345953. PubMed ID: 38726012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.
    Devaux JJ; Miura Y; Fukami Y; Inoue T; Manso C; Belghazi M; Sekiguchi K; Kokubun N; Ichikawa H; Wong AH; Yuki N
    Neurology; 2016 Mar; 86(9):800-7. PubMed ID: 26843559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy: An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey.
    Hashimoto Y; Ogata H; Yamasaki R; Sasaguri T; Ko S; Yamashita K; Xu Z; Matsushita T; Tateishi T; Akiyama S; Maruyama S; Yamamoto A; Kira JI
    Front Neurol; 2018; 9():997. PubMed ID: 30538665
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15.
    Martinez-Martinez L; Lleixà MC; Boera-Carnicero G; Cortese A; Devaux J; Siles A; Rajabally Y; Martinez-Piñeiro A; Carvajal A; Pardo J; Delmont E; Attarian S; Diaz-Manera J; Callegari I; Marchioni E; Franciotta D; Benedetti L; Lauria G; de la Calle Martin O; Juárez C; Illa I; Querol L
    J Neuroinflammation; 2017 Nov; 14(1):224. PubMed ID: 29145880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg.
    Querol L; Nogales-Gadea G; Rojas-Garcia R; Diaz-Manera J; Pardo J; Ortega-Moreno A; Sedano MJ; Gallardo E; Berciano J; Blesa R; Dalmau J; Illa I
    Neurology; 2014 Mar; 82(10):879-86. PubMed ID: 24523485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of neurofilament light in blood in patients with polyneuropathy: A systematic review.
    Kodal LS; Witt AM; Pedersen BS; Aagaard MM; Dysgaard T
    J Peripher Nerv Syst; 2024 Mar; 29(1):17-27. PubMed ID: 38066727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Neurofilament and Free Light Chain Levels in Patients Undergoing Treatment for Chronic Inflammatory Demyelinating Polyneuropathy.
    Luigetti M; Primiano G; Basile V; Vitali F; Pignalosa S; Romano A; Sabino A; Marino M; Di Santo R; Ciasca G; Basile U
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy.
    Maalmi H; Strom A; Petrera A; Hauck SM; Strassburger K; Kuss O; Zaharia OP; Bönhof GJ; Rathmann W; Trenkamp S; Burkart V; Szendroedi J; Ziegler D; Roden M; Herder C;
    Diabetologia; 2023 Mar; 66(3):579-589. PubMed ID: 36472640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.